<DOC>
	<DOCNO>NCT01371630</DOCNO>
	<brief_summary>The goal Phase I part clinical research study test 2 dose level drug inotuzumab ozogamycin find high tolerable dose give combination chemotherapy . The goal Phase II learn inotuzumab ozogamycin give combination chemotherapy help control acute lymphoblastic leukemia ( ALL ) . The safety study drug also study . Participants study least 60 year age newly diagnose ALL refractory-relapsed ALL regardless age . Inotuzumab ozogamycin design attach protein often find leukemia cell . This may cause cancer cell die . Rituximab design attach cancer cell damage , may cause cell die . Hyper-CVD include combination cyclophosphamide , vincristine , dexamethasone , methotrexate , Ara-C ( cytarabine ) , Neulasta ( pegfilgrastim ) . The maintenance therapy use study call POMP , include combination mercaptopurine , methotrexate , vincristine , prednisone . These chemotherapy drug design interfere multiplication cancer cell , may slow stop growth spread throughout body . This may cause cancer cell die .</brief_summary>
	<brief_title>Study Combination Inotuzumab Ozogamycin ( CMC-544 ) With Low-intensity Chemotherapy Patients With Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , participant assign study group base join study . One ( 1 ) group 6 participant enrol Phase I portion study , 1 group 60 participant enrol Phase II . The Phase I group receive low dose level inotuzumab ozogamycin . The Phase II group receive high dose inotuzumab ozogamycin , intolerable side effect see . All participant receive dose level rest study drug . Study Drug Administration : Participant receive 8 cycle induction consolidation therapy possibly 4 cycle blinatumomab treatment . Each induction/consolidation cycle 3-4 week . Blinatumomab cycle 42 day . Hyper-CVD : Cycles 1 , 3 , 7 , 9 : On Days 1-3 Cycles 1 , 3 , 7 , 9 , participant receive cyclophosphamide every 12 hour vein 3 hour . On Days 1-3 Cycles 1 , 3 , 7 , 9 , participant receive mesna continuous infusion start 1 hour participant receive cyclophosphamide end 12 hour last dose cyclophosphamide . Mesna give low risk side effect . On Days 1 8 Cycles 1 , 3 , 7 , 9 ( +/- 2 day ) , participant receive vincristine vein 30 minute . On Days 1-4 11-14 Cycles 1 , 3 , 7 , 9 ( +/- 2 day ) , participant take dexamethasone vein mouth 1 time day . On Days 2 8 Cycles 1 3 ( +/- 2 day ) , participant receive inotuzumab ozogamycin vein 60 minute ( +/- 15 minute ) . The dose participant receives depend participant start treatment . If participant 's doctor think need low risk side effect , participant take acetaminophen , diphenhydramine , hydrocortisone participant 's dos inotuzumab ozogamycin . Acetaminophen give mouth . Diphenhydramine give mouth vein 15-30 minute . Hydrocortisone give vein 15-30 minute . On Days 1 8 Cycles 1 3 ( +/- 2 day ) , participant 's doctor feel participant 's best interest , participant may receive rituximab . The study doctor decide long infusion last . Participant also receive methotrexate alternate cytarabine spinal tap ( intrathecally ) help low risk disease come back fluid surround participant 's brain . A spinal tap ( also call lumbar puncture ) fluid surround spinal cord remove insert needle low back . The affected area numb local anesthetic procedure . It also use give chemotherapy . On Day 2 Cycles 1 3 ( +/- 2 day ) Day 8 Cycles 2 4 , participant receive intrathecal methotrexate . On Day 8 Cycles 1 3 ( +/- 2 day ) Day 5 Cycles 2 4 , participant receive intrathecal cytarabine . On Day 4 Cycles 1 , 3 , 7 , 9 ( +/- 2 day ) participant receive pegfilgrastim injection skin . Methotrexate alternate cytarabine vein : Cycles 2 , 4 , 8 , 10 On Day 1 Cycles 2 , 4 , 6 8 , participant receive methotrexate vein 24 hour ( +/- 3 hour ) . On Days 2 3 Cycles 2 , 4 , 8 , 10 participant receive cytarabine vein 2 time day 3 hour time . On Days 1 8 Cycles 2 4 ( +/- 2 day ) , participant 's doctor feel participant 's best interest , participant may receive rituximab vein 2-6 hour . On Days 2 8 Cycles 2 4 ( +/- 2 day ) , participant receive inotuzumab ozogamycin vein 60 minute ( +/- 15 minute ) . If participant 's doctor think participant 's best interest , participant may receive inotuzumab ozogamycin often . On Day 4 Cycles 2 , 4 , 8 , 10 ( +/- 2 day ) , participant receive pegfilgrastim injection skin . On Days 2-5 Cycles 2 , 4 , 8 , 10 participant receive leucovorin vein 1 hour mouth every 6 hour 8 dos begin 12 hour ( +/- 2 hour ) participant finish receive methotrexate . Leucovorin give low risk side effect . On Days 1-29 Cycles 5-6 11-12 , participant 's doctor think participant 's best interest , participant may receive blinatumomab vein continuous infusion follow 2 week rest without treatment . During Cycle 5 , participant receive low dose Days 1-4 , dose increased Days 5-29 . During Cycles 6 , 11 , 12 , dose day . Participant may ask remain hospital Days 1-6 Cycle 5 Days 1-2 Cycle 6 . If participant tolerating treatment well , participant may receive remain treatment outpatient . Participant ask return MD Anderson specific time , allow home health care provider visit participant home , infusion bag properly change . On Day 1 Cycles 5 , 6 , 11 12 participant receive dexamethasone vein 15 - 30 minute 1 hour begin treatment blinatumomab low risk side effect . Participant 's dose study drug may change depend side effect participant may . Participant may give drug help prevent side effect . Participant 's doctor tell participant drug , give , possible risk . Maintenance Therapy : After participant completes cycle describe , participant receive POMP maintenance therapy 1 year participant receive 4 blinatumomab cycle , otherwise 3 year . Participant take mercaptopurine mouth 2 time day 3 year . Participant take methotrexate mouth 1 time week 3 year . Participant receive vincristine vein 30 minute 1 time month 1 year . Participant take prednisone mouth 1 time day 5 day every month 1 year . If bone marrow sample draw consolidation maintenance therapy show disease go , participant 's doctor may recommend participant receive additional dos inotuzumab ozogamycin . Participant would receive low dose 1 time every 3-4 week 6 dos instead receive POMP maintenance therapy . Study Visits : Within 1 week Day 1 cycle : - Participant physical exam , include measurement participant 's vital sign . - Participant ask participant feeling drug participant may take . - If doctor think need , blood ( 1 tablespoon ) drawn test study drug may affect cancer cell . - If participant receive rituximab participant history irregular heartbeat chest pain due heart trouble , participant ECGs perform rituximab infusion , 1 time infusion , within 2 hour infusion . The rituximab infusion stop participant serious episode irregular heartbeat . Blood ( 1 tablespoon ) drawn routine test 1-3 time week Cycles 1 2 , least every 1-2 week consolidation , every 2-4 week maintenance cycle . Participant bone marrow aspiration and/or biopsy ( 1 teaspoon ) check status disease Days 14-21 ( +/- 3 day ) Cycle 1 , every 2-4 cycle consolidation . Within 1 week Day 1 Cycles 2 , 4 , 6 , 8 , participant chest x-ray check participant 's lung . Every 3 month maintenance : - Participant ask participant feeling drug participant may take . - Participant bone marrow aspiration and/or biopsy ( 1 teaspoon ) . Bone marrow aspiration and/or biopsy may do every 3-6 month begin 2nd year maintenance . The blood draws routine test , bone marrow aspirations/biopsies , ECGs may repeat often anytime doctor think need . Length Treatment : Participant may receive study drug 12 cycle maintenance therapy 3 year . Participant longer able take study drug disease get bad , intolerable side effect occur , participant unable follow study direction . Participation study participant complete follow-up . Follow-up : Participant follow-up visit 30 day participant 's last dose study drug . At visit , participant ask side effect participant may . If participant make clinic visit , do phone member study staff . The phone call last 10 minute . This investigational study . Rituximab , Hyper-CVD , methotrexate , cytarabine , blinatumomab , POMP maintenance drug FDA approve commercially available treatment leukemia . Combining inotuzumab ozogamycin rituximab investigational . Giving inotuzumab ozogamycin patient leukemia investigational . Up 206 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients age 60 year old previously untreated ALL preB , Philadelphia chromosome ( Ph ) negative ALL . Minimal prior therapy ( le 1 week steroid , vincristine , and/or 1 dose anthracycline alkylating agent ) allow . 2 . Zubrod performance status 03 . 3 . Adequate liver function ( bilirubin &lt; /= 1.95 mg/dL SGPT SGOT &lt; /= 3 x upper limit normal [ ULN ] , unless consider due tumor ) , renal function ( creatinine &lt; /= 2 mg/dL ) . Even organ function abnormality consider due tumor , upper limit bilirubin &lt; /= 2.6 mg/dL creatinine &lt; /= 3 mg/dL . 4 . Provision write informed consent . 5 . Patients first remission eligible . 6 . Patients refractoryrelapsed ALL age eligible , provide eligible regimen high priority . 1 . Phpositive ALL , Burkitt 's Leukemia Lymphoma , Tcell ALL lymphoblastic lymphoma . 2 . Patient active heart disease ( NYHA class &gt; /= 3 assessed history physical examination ) . 3 . Patients cardiac ejection fraction ( measure either MUGA echocardiogram ) &lt; 40 % exclude . 4 . Patients active hepatitis exclude . 5 . Pregnant breastfeed woman exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>pre-B , Philadelphia chromosome ( Ph- ) negative</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Inotuzumab Ozogamycin</keyword>
	<keyword>CMC-544</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Neulasta</keyword>
	<keyword>PEG-G-CSF</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>6-Mercaptopurine</keyword>
	<keyword>Mercaptopurine</keyword>
	<keyword>Purinethol</keyword>
	<keyword>6-MP</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Otrexup</keyword>
	<keyword>Rasuvo</keyword>
	<keyword>Rheumatrex</keyword>
	<keyword>Trexall</keyword>
	<keyword>Amethopterin</keyword>
	<keyword>Methotrexate Sodium</keyword>
	<keyword>MTX</keyword>
	<keyword>Oncovin</keyword>
	<keyword>Vincristine Sulfate</keyword>
	<keyword>Vincasar Pfs</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Deltasone</keyword>
	<keyword>Sterapred</keyword>
	<keyword>Rayos</keyword>
	<keyword>Meticorten</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Wellcovorin</keyword>
	<keyword>Calcium Leucovorin</keyword>
	<keyword>Folinic Acid</keyword>
	<keyword>Citrovorum Factor</keyword>
</DOC>